Phase 4 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a specific nerve condition called CIDP (a type of nerve disease causing weakness and numbness), meeting recognised medical guidelines for a definite, probable, or movement-only form of the condition.
- You have never previously been treated with intravenous immunoglobulin (a protein treatment given through a drip) or subcutaneous immunoglobulin (the same treatment given under the skin).
- You are 18 years of age or older.
- You have a certain level of disability in your arms or legs, as measured by a standard score used in nerve disease studies (confirm with trial site).
- You have symptoms including slowly or repeatedly worsening weakness and reduced sensation in your arms and legs, developing over at least 2 months, with reduced or absent reflexes.
- Your nerve tests (electrical tests measuring how well your nerves carry signals) show specific patterns that match the criteria for this condition (confirm with trial site for the detailed technical requirements).
Who may not be able to join:
- You have a different known cause for your nerve problems other than CIDP.
- You have a higher-than-normal risk of developing blood clots.
- You are currently pregnant (all women who could become pregnant will be tested at the start).
- You are currently breastfeeding.
- You have or have had a cancer diagnosis.
- You have another serious medical illness.
- You have received immune-suppressing or immune-modifying treatments in the last 6 months, except for a low dose of steroid (prednisolone under 25 mg per day).
- You have Hepatitis B, Hepatitis C, or HIV (you will be tested for these at the start).
- You are known to have an IgA deficiency (a specific lack of a type of protein in your blood).
- You have a known allergy to the ingredients in either of the two treatments used in this trial (called PRIVIGEN or HIZENTRA).
- You weigh more than 120 kg.
- During the trial, you may need to stop if you become pregnant, develop a serious illness, do not follow the treatment plan, need to start other immune-modifying treatments, experience unacceptable side effects, or choose to withdraw your consent.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Henning Andersen, MD,DMSc,PhD, Aarhus University, Aarhus University Hospital
Phone: +45 20231903
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in disability
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.